'''Bepotastine''' ('''Talion''', '''Bepreve''') is a 2nd generation [[antihistamine]].<ref>{{cite journal |title = Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance |author1=H. Takahashi |author2=A. Ishida-Yamamoto |author3=H. Iizuka |doi = 10.1111/j.1365-2230.2004.01618.x |journal = Clinical and Experimental Dermatology |volume = 29 |pages = 526â€“532 |date = September 2004 |url = http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2230.2004.01618.x/abstract;jsessionid=187F07A8705C6C93F1442C20957A795D.d03t03?deniedAccessCustomisedMessage=&userIsAuthenticated=false}}</ref> It was approved in [[Japan]] for use in the treatment of [[allergic rhinitis]] and [[urticaria]]/[[pruritus]] in July 2000 and January 2002, respectively. It is currently marketed in the United States under the brand-name Bepreve, by [[ISTA Pharmaceuticals]].

 
Bepotastine is available as an [[Ophthalmology|ophthalmic]] solution and oral tablet. It is a direct [[h1 antagonist|H<sub>1</sub>-receptor antagonist]] that inhibits the release of [[histamine]] from [[mast cell]]s.<ref>{{cite journal |title = Bepotastine Monograph |journal = LexiComp |url = http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/1844380#f_pharmacology-and-pharmacokinetics}}</ref> The ophthalmic formulation has shown minimal systemic absorption, between 1 and 1.5% in healthy adults.<ref name=":0">{{Cite web|url = http://www.bausch.com/Portals/109/-/m/BL/United%20States/Files/Downloads/ECP/Pharma/BEPREVE-Prescribing-Info.pdf|title = Bepreve prescribing Information|date = |accessdate = |website = |publisher = }}</ref> Common side effects are eye irritation, headache, unpleasant taste, and nasopharyngitis.<ref name=":0" /> The main route of elimination is urinary excretion, 75-90% excreted unchanged.<ref name=":0" />
